Establishment Labs (NASDAQ:ESTA) and Vicarious Surgical (NYSE:RBOT) Financial Survey

Establishment Labs (NASDAQ:ESTAGet Rating) and Vicarious Surgical (NYSE:RBOTGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares Establishment Labs and Vicarious Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Establishment Labs -29.77% -70.10% -27.60%
Vicarious Surgical N/A -116.85% -29.32%

Institutional & Insider Ownership

77.8% of Establishment Labs shares are owned by institutional investors. Comparatively, 35.3% of Vicarious Surgical shares are owned by institutional investors. 13.1% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Establishment Labs and Vicarious Surgical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Establishment Labs $126.68 million 12.33 -$41.14 million ($1.66) -38.89
Vicarious Surgical N/A N/A -$35.21 million N/A N/A

Vicarious Surgical has lower revenue, but higher earnings than Establishment Labs.

Risk and Volatility

Establishment Labs has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Vicarious Surgical has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Establishment Labs and Vicarious Surgical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Establishment Labs 0 1 2 0 2.67
Vicarious Surgical 0 1 3 0 2.75

Establishment Labs presently has a consensus target price of $99.40, suggesting a potential upside of 53.97%. Vicarious Surgical has a consensus target price of $10.75, suggesting a potential upside of 139.96%. Given Vicarious Surgical’s stronger consensus rating and higher probable upside, analysts plainly believe Vicarious Surgical is more favorable than Establishment Labs.

Summary

Establishment Labs beats Vicarious Surgical on 6 of the 11 factors compared between the two stocks.

About Establishment Labs

(Get Rating)

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

About Vicarious Surgical

(Get Rating)

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.